Alkermes to Hold Virtual Investor Day

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) will host a virtual Investor Day on March 25, 2021, at 9:00 a.m. ET. Senior management will share insights on the company's research and development strategy in neuroscience and oncology and discuss clinical data related to nemvaleukin alfa (ALKS 4230). The event will also highlight earlier stage programs, including ALKS 1140, and cover the Value Enhancement Plan initiated in December 2020. Investors can pre-register for the webcast on the company’s website.

Positive

• Announcement of a virtual Investor Day to engage with investors on March 25, 2021.
• Discussion of promising research in neuroscience and oncology, focusing on nemvaleukin alfa and ALKS 1140.
• Reiteration of the Value Enhancement Plan, indicating ongoing strategic initiatives.

Negative

• None.

DUBLIN, March 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will hold a virtual Investor Day on Thursday, March 25, 2021, beginning at 9:00 a.m. ET (1:00 p.m. GMT). During the event, members of Alkermes' senior management and research and development team will discuss the company's research and development strategy in neuroscience and oncology, review clinical data and strategy related to nemvaleukin alfa (ALKS 4230) and highlight the company's earlier stage development programs, including ALKS 1140. The company will also discuss the Value Enhancement Plan announced in December 2020.

Pre-registration for the webcast is available on the Investors section of the company's website at www.alkermes.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start. A replay of the webcast will be archived on the Investors section of the company's website at www.alkermes.com for 30 days following the presentation.

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Contact:
Alex Braun
Investor Relations
+1 781 296 8493

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-to-hold-virtual-investor-day-301240385.html

SOURCE Alkermes plc

FAQ

What is the date of Alkermes' virtual Investor Day?

Alkermes' virtual Investor Day is scheduled for March 25, 2021.

What will be discussed during the Alkermes Investor Day?

Senior management will discuss the research and development strategy, clinical data related to nemvaleukin alfa (ALKS 4230), and earlier stage development programs.

Where can I find the webcast for Alkermes' Investor Day?

The webcast for Alkermes' Investor Day can be found in the Investors section of their website.

What is nemvaleukin alfa (ALKS 4230)?

Nemvaleukin alfa (ALKS 4230) is a product candidate being discussed for its clinical data during the Investor Day.